Table 1.
Characteristics of patients with pT0 prostate cancer
| Patient number | Age | PSA (ng/mL)) | Duration of NHT | Clinical stage | GS | Number of positive cores on biopsy | Maximal tumor length on biopsy (mm) | Duration of follow-up | |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | After NHT | ||||||||
| 1 | 66 | 24.6 | <0.1 | 6 months | T2cNoMo | 7 | 6 | 10.0 | 48 |
| 2 | 77 | 55.3 | 0.3 | 3 months | T3aN0M0 | 6 | 3 | 3.0 | 60 |
| 3 | 66 | 20.9 | <0.1 | 6 months | T3aN0M0 | 7 | 3 | 21.0 | 80 |
| 4 | 76 | 6.18 | <0.1 | 3 months | T2cNoMo | 7 | 8 | 12.0 | 74 |
| 5 | 73 | 9.4 | <0.1 | 12 months | T3aN0M0 | 7 | 8 | 5.0 | 57 |
| 6 | 74 | 19.38 | <0.1 | 6 months | T3aN0M0 | 8 | 6 | 10.0 | 6 |
PSA prostate-specific antigen, NHT neoadjuvant hormonal therapy, GS Gleason score